Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients

British Journal of Clinical Pharmacology

Volumn 48, Issue 4, 1999, Pages 610-615

  Yeo, K Rowland ^a   Yeo, W W ^a   Wallis, E J ^a   Ramsay, L E ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Cholesterol reduction; CYP3A4; Diltiazem; Interaction; Simvastatin

Indexed keywords

CHOLESTEROL; DILTIAZEM; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SECONDARY PREVENTION; SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL; DATA COLLECTION; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PATIENT DROPOUTS; SIMVASTATIN;

EID: 0032827824     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00066.x     Document Type: Article

References (27)

1. 1 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. 2 Prueksaritanont T, Gorham LM, Bennett MA, et al. In vitro metabolism of simvastatin in humans - identification of metabolising enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191-1199.
3. 3 Haq IUL, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci 1996; 91: 399-413.
4. 4 Sutton D, Butler AM, Nadin L, Murray M. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidised diltiazem metabolites. J Pharmacol Exp Ther 1997; 282: 294-300.
5. 5 Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64: 369-377.
6. 6 Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy 3-methyl-glutaryl-coenzyme A reductase inhibitors. Clin Pharmacokin 1996; 31: 348-371.
7. 7 Standing Medical Advisory Committee on use of statins. NHS Executive London: Department of Health, May 1997.
8. 8 Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80: 106.
9. 9 Armitage P, Berry G. Statistical methods in medical research, 2nd Edn, Oxford: Blackwell Scientific Publications, 1987: pp. 484 498.
10. 10 Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R. on behalf of the Societies. Joint British recommendations on prevention of coronary heart disease in Clinical Practice. Heart 1998; 80 supplement 2: S1-S29.
11. 11 Brockmoller J, Neumayer HH, Wagner K, Weber W, Heinemeyer G, Kewitz H, Roots I. Pharmacokinetic interaction between cyclosporin and diltiazem. Eur J Clin Pharmacol 1990; 38: 237-242.
12. 12 Valentine H, Koegh A, McIntosh N, Hunt S, Oyer P, Schroeder J. Cost containment: coadministration of diltiazem with cyclosporin after heart transplantation. J Heart Lung Transplant 1992; 11: 1-8.
13. 13 Al Edreesi M, Caliile G, Dupuis C, Theoret Y, Paradis K. Safety, tolerability, and pharmacokinetic actions of diltiazem in pediatric liver transplant recipients on cyclosporin. Liver Transplantation Surgery 1995; 1: 383-388.
14. 14 Chrysostomou A, Walker RG, Russ GR, d'Apice AJ, Kincaid-Smith P, Matthew TH. Diltiazem in renal allograft recipients receiving cyclosporin. Transplantation 1993; 55: 300-304.
15. 15 Jones TE. Survey of cyclosporin sparing agent use in Australasian transplant centres. Aust NZ J Med 1996; 26: 772-776.
16. 16 Abernethy DR, Montamat SC. Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. Am J Cardiol 1987; 60: 1161-1201.
17. 17 Ohashi K, Sudo T, Sakamoto K, Tateishi T, Fujimara Y, Ebihara A. The influence of pretreatment periods with diltiazem on nifedipine kinetics. J Clin Pharmacol 1993; 33: 222-225.
18. 18 Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37: 221-225.
19. 19 Crocker JF, Renton KW, Le Vatte TL, McLellan DH. The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients. Hypertension 1996; 28: 109-114.
20. 20 Stein E, Sprecher D, Allenby KS, Tosiello MS, Whalen E, Ripa SR. Cerivastatin, a new potent syntheic HMG-CoA Reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolacmia. J Cardiovasc Pharmacol Ther 1997; 2: 7-16.
21. 21 Miettinen TA, Gylling H, Strandberg T, Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Br Med J 1998; 316: 1127-1130.
22. 22 Segaert MF, De Soete C, Vandewicle I, Verbanck J. Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transplant 1996; 11: 1846-1847.
23. 23 Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998; 351: 1929.
24. 24 Neuvonen PJ, Kantola T, Kivisto KT. Calcium channel blocker-simvastatin interaction. Clin Pharmacol Ther 1999; 65: 583.
25. 25 Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-182.
26. 26 Yang BB, Siedlek PH, Smithers JA, Sedman AJ, Stern RH. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: erythromycin and ethinyl estradiol. Pharmacol Res 1996; 13(Suppl 9): S437.
27. 27 Wierzbicki AS, Reynolds TM, Crook MA, Tatler J, Peters BS. Lipid lowering therapy in patients with HIV infection. Lancet 1998; 352: 1782.